Day 5 on Ozempic: what early results actually mean

What's this video probably claiming?

Based on the caption translating roughly to "This is day five, thank God everything is improving," combined with the #ozempic hashtag and #dietchallenge framing, this creator is almost certainly documenting early positive changes on a GLP-1 receptor agonist, most likely semaglutide. Day-five content on TikTok follows a very predictable pattern: reduced appetite, less food noise, maybe a pound or two down on the scale, and a general sense that the medication is "working." Some creators in this format also report reduced bloating or changed food cravings. The tone of gratitude and progress is common in early GLP-1 diary content, and the hashtag combination suggests the creator is participating in a structured or self-imposed diet challenge alongside the medication. This is not inherently harmful content, but early-day enthusiasm tends to skip over the clinical complexity of what GLP-1 drugs actually do and how long meaningful outcomes take to materialize.

What does the science actually show?

Here is the part most day-five videos get wrong by omission. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed that patients on 2.4 mg weekly semaglutide lost a mean of 14.9% of body weight, but that was over 68 weeks, not five days. The titration schedule for Wegovy starts at 0.25 mg weekly for the first four weeks specifically to minimize gastrointestinal side effects. That means at day five, the vast majority of users are on a sub-therapeutic dose. Any appetite suppression felt this early is real but likely reflects the initial GLP-1 receptor activation rather than the steady-state pharmacokinetics that drive long-term results. Tirzepatide data from the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed up to 22.5% weight loss at 72 weeks. Neither drug delivers its clinical benefit in the first week. Feeling better on day five is not the same as the drug working at its documented efficacy level.

Where does the social media noise diverge from clinical reality?

The GLP-1 TikTok genre has a structural problem. Creators document the honeymoon phase, the first few weeks when appetite drops noticeably and the scale moves quickly because of water weight and reduced caloric intake. What gets far fewer views is the plateau at weeks 12 to 20, the dose adjustment conversations, or the gastrointestinal side effects that hit roughly 44% of semaglutide users according to the STEP trials. A 2023 analysis in Obesity Reviews (Ard et al.) found that social media portrayals of GLP-1 medications significantly underrepresent side effect incidence and overrepresent speed of results. Day-five diary videos also rarely mention that these are prescription medications requiring clinical oversight, that compounded semaglutide is not equivalent to brand-name Wegovy or Ozempic, and that stopping the medication typically results in weight regain, with data from Wilding et al. 2022 showing two-thirds of lost weight returning within a year of discontinuation.

What should you actually know?

If you are considering a GLP-1 medication after watching content like this, the clinical picture is more complicated than five-day optimism suggests. These medications require a prescriber, baseline labs, and ongoing monitoring. The FDA-approved indication for semaglutide 2.4 mg (Wegovy) is adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. Liraglutide (Saxenda) has a similar indication. Tirzepatide (Zepbound) was FDA-approved for obesity in November 2023. None of these are short-term tools. The SCALE Obesity trial (Pi-Sunyer et al., 2015, NEJM) showed liraglutide required 56 weeks of treatment to demonstrate its full weight-loss profile. Early improvement is a signal the medication is tolerated, not a signal that the hard work is done. Talk to a licensed provider, not a TikTok day-five diary, before making any decisions about these medications.